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Abstract
Background: Status epilepticus (SE) is an acute, prolonged epileptic crisis with a mortality rate of 20–30%; the underlying
mechanism is not completely understood. We assessed the hypothesis that brain stem cardiovascular dysregulation occurs
during SE because of oxidative stress in rostral ventrolateral medulla (RVLM), a key nucleus of the baroreflex loop; to be
ameliorated by brain-derived neurotrophic factor (BDNF) via an antioxidant action.
Methodology/Principal Findings: In a clinically relevant experimental model of temporal lobe SE (TLSE) using Sprague-
Dawley rats, sustained hippocampal seizure activity was accompanied by progressive hypotension that was preceded by a
reduction in baroreflex-mediated sympathetic vasomotor tone; heart rate and baroreflex-mediated cardiac responses
remained unaltered. Biochemical experiments further showed concurrent augmentation of superoxide anion,
phosphorylated p47
phox subunit of NADPH oxidase and mRNA or protein levels of BDNF, tropomyosin receptor kinase B
(TrkB), angiotensin AT1 receptor subtype (AT1R), nitric oxide synthase II (NOS II) or peroxynitrite in RVLM. Whereas
pretreatment by microinjection bilaterally into RVLM of a superoxide dismutase mimetic (tempol), a specific antagonist of
NADPH oxidase (apocynin) or an AT1R antagonist (losartan) blunted significantly the augmented superoxide anion or
phosphorylated p47
phox subunit in RVLM, hypotension and the reduced baroreflex-mediated sympathetic vasomotor tone
during experimental TLSE, pretreatment with a recombinant human TrkB-Fc fusion protein or an antisense bdnf
oligonucleotide significantly potentiated all those events, alongside peroxynitrite. However, none of the pretreatments
affected the insignificant changes in heart rate and baroreflex-mediated cardiac responses.
Conclusions/Significance: We conclude that formation of peroxynitrite by a reaction between superoxide anion generated
by NADPH oxidase in RVLM on activation by AT1R and NOS II-derived NO leads to a reduction in baroreflex-mediated
sympathetic vasomotor tone during experimental TLSE; to be ameliorated by the upregulated BDNF/TrkB signaling via
inhibition of p47
phox phosphorylation. This information offers a new vista in devising therapeutic strategy towards
minimizing mortality associated with TLSE.
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Introduction
Status epilepticus (SE) is an acute, prolonged epileptic crisis and
is a common, life-threatening neurological disorder [1,2]. As a
medical emergency, SE has a mortality rate that ranges between
20 and 30% [3,4]. A majority of the studies that addresses the
mechanisms that underlie the mortality associated with SE has
included the heart as the primary target. Thus, lethal cardiac
arrhythmias [4,5] or cardiac damage that increases the suscepti-
bility to arrhythmia [6,7] after SE have been reported. Two pieces
of information further implicate a potential role for brain stem
cardiovascular regulation in SE-linked mortality. First, as SE
continues, the prominent elevation in systemic arterial pressure
exhibited at the beginning of SE shifts to a decrease to levels below
baseline [8]. Second, seizures activate areas in the medulla
oblongata [9,10], including nucleus tractus solitarii (NTS) and
rostral ventrolateral medulla (RVLM), that are associated with
brain stem cardiovascular regulation [11,12].
The most fundamental mechanism in brain stem cardiovascular
regulation exists in the form of baroreflex, which provides a rapid
negative feedback mechanism that dampens fluctuations in
circulatory parameters induced by environmental insults [11,12].
The carotid sinus and aortic depressor nerves convey primary
baroreceptor afferent information to NTS. Outputs from NTS
modulate the activity of parasympathetic premotor neurons in the
dorsal motor nucleus of vagus or nucleus ambiguus that mediate
reflex control of the heart; as well as the reticulospinal vasomotor
neurons in RVLM that mediate reflex adjustment of sympathetic
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conditions, baroreflex is responsible for the maintenance of stable
arterial pressure (AP). Severe and even fatal consequences,
however, will take place under pathological conditions when the
baroreflex is dysregulated. Whether dysfunction of baroreflex-
mediated cardiac and vasomotor responses is associated with SE,
and detailed underlying cellular and molecular mechanisms, are
wanting.
The reactive oxygen species (ROS), including free radicals such
as superoxide anion, are produced virtually by all aerobic cells.
The production and removal of ROS are tightly controlled under
physiological conditions. Nonetheless, under pathological situa-
tions, excessive production of ROS may surpass the endogenous
antioxidant defense mechanisms for the degradation of ROS,
leading to conditions that are referred to as oxidative stress. An
increasing body of evidence suggests that oxidative stress is
involved in the pathogenesis of many cardiovascular diseases [13–
15]. In terms of brain stem cardiovascular regulation, clinical and
animal studies [16,17] demonstrated that oxidative stress impairs
baroreflex sensitivity (BRS).
Superimposed on its classical trophic functions in the peripheral
and central nervous system during development [18] or in synaptic
activity and plasticity of mature neurons [19], brain-derived
neurotrophic factor (BDNF) is now known to possess nontrophic
actions [20]. In addition to neuroprotective effects, which defend
neurons against injury and diseases [21–23], there are indications
that BDNF possesses an antioxidant action [24,25]. Moreover,
BDNF and its receptor, tropomyosin receptor kinase B (TrkB) are
distributed in brain stem nuclei that subserve cardiovascular
regulation [26–28]. With particular relevance to the present study,
our laboratory showed [29] recently that BDNF plays an active
role in neural regulation of AP by maintaining ROS, particularly
superoxide anion homeostasis in RVLM.
Our laboratory has developed an experimental model of SE
that is coupled with temporal lobe epilepsy [30–32], the most
common form of epilepsy [33]. Based on this experimental TLSE
model and employing RVLM as the target neural substrate, the
present study assessed the hypothesis that oxidative stress in
RVLM, leading to brain stem cardiovascular dysregulation occurs
during TLSE; to be ameliorated by BDNF via an antioxidant
action. Our complementary physiological, pharmacological and
biochemical results validated this hypothesis.
Results
Experimental temporal lobe status epilepsy
An experimental model [30–32] that mimics the clinical
manifestations of TLSE was used. As reported previously,
microinjection unilaterally of kainic acid (KA; 0.5 nmol) into the
left hippocampal CA3 subfield elicited a significant and sustained
buildup of seizure-like hippocampal EEG activity (Figure 1A) that
can be quantified by the progressive and concomitant increase in
both root mean square (Figure 1B) and mean power frequency
(Figure 1C) values of hippocampal EEG signals recorded from the
CA3 subfield on the right side. On the other hand, unilateral
application of the solvent, phosphate-buffered saline (PBS) to the
left hippocampal CA3 subfield was ineffective (Figure 1B,C). For
the purpose of the present study, we routinely recorded those
seizure activities for 180 min after induction.
Reduced baroreflex-mediated sympathetic vasomotor
tone during experimental TLSE
Simultaneous evaluation of hemodynamic parameters (Figure 2)
revealed that whereas mean arterial pressure (MAP) underwent a
progressive reduction that became statistically significant 80 min
after the induction of experimental TLSE, heart rate (HR)
remained stable during the 180-min observation period. Mecha-
nistic delineations using auto-spectral analysis of systolic blood
pressure (SBP) signals indicated a progressive reduction in
baroreflex-mediated sympathetic vasomotor tone [34], as denoted
by a significant decrease in the power density of the low-frequency
(BLF) component in the SBP spectrum, 20 min before significant
hypotension took place. On the other hand, evaluation of
baroreflex-mediated cardiac responses using the sequence method
[35] showed that BRS exhibited insignificant alterations over 180-
min after the induction of experimental TLSE. Likewise, cross-
spectral analysis based on changes in the gain of transfer function
between pulse interval (PI) and SBP spectra at the low-frequency
(LF) and high-frequency (HF) bands, which respectively represents
the influence of baroreflex-mediated sympathetic and vagal
regulation on the heart [35], also showed insignificant changes.
Again, unilateral microinjection of PBS into the left hippocampal
CA3 subfield exerted no significant changes in all parameters
examined (Figure 2).
Oxidative stress in RVLM during experimental TLSE
As the origin of the BLF component in the SBP spectrum [36],
RVLM presents itself as a logical neural substrate for further
biochemical evaluations. Based on the relative intensity of
fluorescence emitted by hydroxyethidium [37], the specific
reaction product between hydroethidine and superoxide anion,
we found a significant elevation of superoxide anion level in
RVLM during experimental TLSE (Figure 3B,F). The specificity
of this demonstrated oxidative stress was confirmed by two
observations. First, minimal amount of fluorescence was detected
in animals that received microinjection of hydroethidine bilaterally
into RVLM without the induction of experimental TLSE
(Figure 3A,F) or in vehicle-controls (Figure 3F). Second, hydro-
ethidine microinjected to sites immediately adjacent to RVLM in
animals that were subject to experimental TLSE also exhibited
minimal amount of fluorescence (Figure 3C). Pretreatment with
microinjection bilaterally of a superoxide dismutase mimetic [38],
tempol (200 pmol) into RVLM significantly blunted the elevation
of superoxide anion level in RVLM (Figure 3D,F). We further
showed that one of the sources of superoxide anion is NADPH
oxidase. Microinjection bilaterally of a specific antagonist of
NADPH oxidase [39], apocynin (2 nmol) into bilateral RVLM
antagonized significantly the augmented level of superoxide anion
(Figure 3F). In addition, co-immunoprecipitation experiments
demonstrated a significant increase in phosphorylated p47
phox
subunit of NADPH oxidase in RVLM during experimental TLSE
(Figure 3G) when compared to sham-controls or vehicle-controls.
Oxidative stress in RVLM underlies the reduced
baroreflex-mediated sympathetic vasomotor tone during
experimental TLSE
Pretreatment by microinjection of tempol (200 pmol) or
apocynin (2 nmol), but not their solvents, into bilateral RVLM
significantly blunted the reduction in MAP and power density of
BLF component during experimental TLSE (Figure 4). Both
pretreatments, however, exerted minimal effects on the insignif-
icant changes in HR or BRS (Figure 4). We further investigated
the role of angiotensin AT1 receptor subtype (AT1R) at RVLM in
the reduced baroreflex-mediated sympathetic vasomotor tone
because previous work from our laboratory [29,40] showed that
activation of AT1R results in oxidative stress in RVLM. In
addition to significantly blunted the elevated superoxide anion
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phox subunit (Figure 3G) in
RVLM, microinjection of an AT1R antagonist [41], losartan
(2 nmol) bilaterally into RVLM resulted in an antagonism of the
depressed MAP and BLF power that was reminiscent of tempol or
apocynin pretreatment (Figure 5), without affecting HR or BRS.
On the other hand, pretreatment with an equimolar dose of an
AT2R antagonist [42], PD123319 (2 nmol), similar to vehicle-
control, was ineffective against the elicited oxidative stress
(Figure 3F,G) or cardiovascular events (Figure 5).
Upregulation of BDNF and TrkB exerts an antioxidant
action in RVLM during experimental TLSE
Quantification by ELISA revealed a progressive elevation of
BDNF level in RVLM during experimental TLSE (Figure 6B).
Real-time PCR further showed that this elevation may result from
transcriptional upregulation of bdnf gene (Figure 6A). There was
also an augmentation of serum level of BDNF (sham:
32.662.3 pg/ml; TLSE: 48.661.9 pg/ml; mean 6 SEM, P,0.05,
n=5–7 animals per group). Likewise, TrkB underwent an augmen-
tation at the mRNA (Figure 6C) or protein (Figure 6D) level in
RVLM. More importantly, pretreatment with microinjection into
bilateral RVLM of a recombinant human TrkB-Fc fusion protein
(TrkB-Fc; 1.5 pmol) [29], which sequesters endogenously released
TrkB ligands and blocks TrkB [43], but not the solvent, significantly
potentiated the already elevated superoxide anion levels (Figure 3F)
or phosphorylated p47
phox subunit (Figure 3G) in RVLM after the
induction of experimental TLSE. Knock-down of bdnf gene with an
antisense oligonucleotide (100 pmol) similarly potentiated the
augmented superoxide anion level (Figure 3E,F) and activation of
NADPH oxidase in RVLM (Figure 3G).
Upregulation of BDNF and TrkB in RVLM amelioriates the
reduced baroreflex-mediated sympathetic vasomotor
tone during experimental TLSE
Pretreatment by applying TrkB-Fc (1.5 pmol) (Figure 7) or an
antisense oligonucleotide against bdnf gene (100 pmol) (Figure 8) to
RVLM also significantly exacerbated the reduction in MAP and
power density of BLF component of SBP signals during
Figure 1. Manifestation of seizure-like hippocampal electroencephalographic activity during experimental temporal lobe status
epilepticus (TLSE). Representative original tracings (A) and summary of temporal changes in root mean square (RMS) (B) or mean power frequency
(MPF) (C) values of seizure-like hippocampal electroencephalographic activity recorded from the CA3 subfield on the right side on microinjection of
kainic acid (KA; 0.5 nmol) or 0.1 M phosphate buffered saline (PBS, pH 7.4) unilaterally to the left CA3 area (at arrow). Values are mean 6 SEM from 5–
7 animals per experimental group. *P,0.05 versus PBS group at corresponding time-points in the post hoc Scheffe ´ multiple-range test.
B=preinjection baseline.
doi:10.1371/journal.pone.0033527.g001
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(0.75 pmol; Figure 7) or antisense oligonucleotide against bdnf gene
(50 pmol; Figure 8) was ineffective, as were control pretreatments
(Figures 7 and 8) with a recombinant human TrkA-Fc fusion
protein (TrkA-Fc; 1.5 pmol), a sense oligonucleotide against bdnf
gene (100 pmol) or the solvents. All pretreatments also exerted
minimal effects on the insignificant changes in HR or BRS
(Figures 7 and 8).
BDNF and TrkB reduce the upregulated peroxynitrite in
RVLM during experimental TLSE
Results from Western blot analysis showed a significant increase
in nitric oxide synthase II (NOS II) expression (Figure 9A); and
ELISA revealed a significant elevation in nitrotyrosine, an experi-
mental index for peroxynitrite (Figure 9B) during experimental
TLSE. Of note was that pretreatments with an antisense oligonu-
cleotide against bdnf gene (100 pmol) or TrkB-Fc (1.5 pmol) further
augmented nitrotyrosine expression in RVLM (Figure 9B), without
affecting the elevated NOS II level (Figure 9A).
Upregulation of BDNF and TrkB is not a consequence of
oxidative stress in RVLM
We reported recently [29] that chronic infusion of angiotensin
II (Ang II) induces AT1R- and superoxide-dependent upregula-
tion of BDNF in RVLM. It would therefore be of interest to
delineate whether the same cellular events occur during
Figure 2. Reduced baroreflex-mediated sympathetic vasomotor tone during experimental TLSE. Temporal changes in mean arterial
pressure (MAP) (A), heart rate (HR;) (B), power density of the low-frequency (BLF) component of systolic blood pressure (SBP) spectrum (C), baroreflex
sensitivity (BRS) (D), and gain of transfer function between pulse interval and SBP spectra at the low-frequency (LF) (E) or high-frequency (HF) (F)
bands on microinjection of KA (0.5 nmol) or PBS into the left hippocampal CA3 subfield (at arrow). Values are mean 6 SEM from 5–7 animals per
experimental group. *P,0.05 versus PBS group at corresponding time-points in the post hoc Scheffe ´ multiple-range test. B=preinjection baseline.
doi:10.1371/journal.pone.0033527.g002
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of losartan (2 nmol), PD123319 (2 nmol), tempol (200 pmol) or
apocynin (2 nmol) into RVLM, similar to vehicle-controls, did not
elicit significant effects on the upregulated BDNF (Figure 10A) or
TrkB (Figure 10B) mRNA in RVLM during experimental TLSE.
BDNF and TrkB do not interact with AT1R in RVLM
Real-time PCR and Western blot analysis revealed that both
mRNA and protein levels of AT1R in RVLM were significantly
augmented after the induction of experimental TLSE
(Figure 11A,B). This induced upregulation of AT1R, however,
was not affected by pretreatments with microinjection of antisense
or sense oligonucleotide against bdnf gene (100 pmol), TrkA-Fc
(1.5 pmol) or TrkB-Fc (1.5 pmol) into the bilateral RVLM
(Figure 11A,B). At the same time, the mRNA and protein levels
of AT2R in RVLM exhibited no significant alterations during
experimental TLSE, and were similarly unaffected by the above
pretreatments (Figure 11C,D).
Figure 3. Oxidative stress in RVLM during experimental TLSE. (A–E) Representative photomicrographs showing the relative intensity (inset)
of fluorescence emitted by 2-hydroxyethidium, the specific reaction product between superoxide and hydroethidine (HEt), which was microinjected
into RVLM (B) or immediately outside RVLM (C) before application of KA (0.5 nmol) into the left hippocampal CA3 subfield of animals that received
pretreatment by microinjection into the bilateral RVLM of distilled water or 0.1 M PBS (Veh) (B,C), tempol (D) or an antisense oligonucleotide (ASON)
against bdnf gene (E). Note minimal fluorescence when HEt was applied to RVLM in animals that received no further experimental manipulations (A).
Scale bar, 200 mm. Note that the relative position of RVLM in (C) is denoted by a circle in dashed line. (F–G) Summary of relative intensity of
superoxide anion based on 2-hydroxyethidium fluorescence at RVLM (F) or the percentage of phosphoserine (p-serine) relative to p47
phox obtained
from the cytosolic fraction of proteins extracted from RVLM that were immunoprecipitated by an anti-p47
phox antiserum, followed by Western blot
analysis of p-serine or p47
phox, 180 min after microinjection of KA (0.5 nmol) or PBS into the left hippocampal CA3 subfield of animals that received
pretreatment by application into the bilateral RVLM of distilled water, 1% DMSO or 0.1 M PBS (Veh), losartan (2 nmol), PD123319 (2 nmol), tempol
(200 pmol), apocynin (2 nmol), BDNF ASON (100 pmol) or a recombinant human TrkB-Fc fusion protein (TrkB-Fc; 1.5 pmol). Values are mean 6 SEM
from 5–7 animals per experimental group.*P,0.05 versus HEt alone or Veh+PBS group, and
+P,0.05 versus Veh+KA group in the post hoc Scheffe ´
multiple-range test. Note that in (G), dividing lines are placed on the gel images to denote groupings of images from different parts of the same gel
or from different gels. Note also that since similar results were obtained from 0.1 M PBS, 1% DMSO or distilled water pretreatments, they were
represented collectively by Veh in this and Figures 4–5 and 7–12 for clarity.
doi:10.1371/journal.pone.0033527.g003
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in the reduced baroreflex-mediated sympathetic
vasomotor tone during experimental TLSE
Pretreatment by microinjection of a NMDA antagonist [44],
MK-801 (500 pmol) into bilateral RVLM, similar to the vehicle,
did not result in significant alterations of the reduction in MAP
and power density of BLF component of SBP spectrum during
experimental TLSE (Figure 12). MK-801 pretreatment also
exerted minimal effects on the insignificant changes in HR or
BRS (Figure 12).
Discussion
Based on complementary physiological, pharmacological
and biochemical evaluations, in associated with a clinically-
compatible animal model, the present study revealed that
upregulation of AT1R, which leads to oxidative stress that results
in the formation of peroxynitrite by a reaction between the
augmented superoxide anion and NOS II-derived NO in RVLM,
underpins the reduction in baroreflex-mediated sympathetic
vasomotor tone that takes place during experimental TLSE.
Furthermore, upregulation of BDNF and TrkB in RVLM
ameliorates this brain stem cardiovascular dysregulation via an
antioxidant action.
A majority of studies that evaluates baroreflex functions
measures primarily the associated cardiac responses; much less
attention is paid to the vasomotor responses. It is therefore of
interest that, by concurrently evaluating both forms of responses,
the present study demonstrated that a significant reduction in
baroreflex-mediated sympathetic vasomotor tone, which precedes
significant hypotension, takes place during experimental TLSE.
Intriguingly, the capacity for baroreflex-mediated sympathetic and
vagal regulation of cardiac functions remains intact. An important
functional implication of those observations is that baroreflex-
mediated responses in heart and blood vessels do not necessarily
have to take place in a concomitant fashion as generally assumed.
More than 90% of SE-induced mortality does not occur during the
seizures, but after a time lag following the seizure episode [45,46].
The mechanism of this extended period of risk is not completely
understood. The present study revealed that it is likely that HR is
sustained during experimental TLSE because of the maintained
baroreflex modulation of the heart. Deterioration of this
homeostatic mechanism in the face of the already dysregulated
baroreflex-mediated sympathetic vasomotor tone over time may
offer a mechanistic underpinning for the delayed mortality
following SE.
The present study revealed that oxidative stress in RVLM
underlies the reduction in baroreflex-mediated sympathetic
vasomotor tone during experimental TLSE. Specifically, our
results indicated that activation of p47
phox subunit of NADPH
oxidase is responsible for the augmented superoxide anion level in
RVLM. NADPH oxidase is a major source for Ang II-elicited
Figure 4. Oxidative stress in RVLM underlies the reduced baroreflex-mediated sympathetic vasomotor tone during experimental
TLSE. Temporal changes in MAP (A), power density of the BLF component (B), HR (C) or BRS (D) after microinjection of KA (0.5 nmol) or PBS into the
left hippocampal CA3 subfield (at arrow) of animals that received pretreatment by application into the bilateral RVLM of distilled water or 1% DMSO
(Veh), tempol (200 pmol) or apocynin (2 nmol). Values are mean 6 SEM from 5–7 animals per experimental group.*P,0.05 versus Veh+PBS group,
and
+P,0.05 versus Veh+KA group at corresponding time-points in the post hoc Scheffe ´ multiple-range test. B=preinjection baseline.
doi:10.1371/journal.pone.0033527.g004
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vation is a multistep process that is initiated by serine
phosphorylation of the cytosolic regulatory p47
phox subunit
[48,49]. Our observed upregulation of AT1R in RVLM, along
with an antagonism of the elevated superoxide anion, phosphor-
ylated p47
phox subunit and progressive reduction in MAP or
power density of BLF component of SBP spectrum by losartan,
tempol or apocynin therefore suggests that the repertoire of
cellular events in RVLM during experimental TLSE includes
activation of AT1R, followed by augmented level of superoxide
anion generated by the triggered p47
phox subunit of NADPH
oxidase that leads to a reduction in baroreflex-mediated
sympathetic vasomotor tone.
Oxidative stress in RVLM is known to be associated with the
hypertensive state in animal models [50]. This notion seemingly
contradicts our observed progressive reduction in MAP and
baroreflex-mediated sympathetic vasomotor tone during experi-
mental TLSE that is causally related to an elevation in superoxide
level in RVLM. A potential solution to this paradox arises from
two pieces of information from our previous work. First, NOS II is
tonically active in RVLM [51]. Second, formation of peroxynitrite
by a reaction between NOS II-derived NO and superoxide anion
in RVLM results in a progressive decrease in MAP and the power
density of the BLF component [52]. This solution is substantiated
by the significantly elevated NOS II and nitrotyrosine (an
experimental index of peroxynitrite) in RVLM observed during
experimental TLSE. It follows that it is the formation of
peroxynitrite because of the upregulated superoxide anion and
NOS II-derived NO in RVLM that underpins the reduction in
baroreflex-mediated sympathetic vasomotor tone, which leads to
the decrease in MAP during experimental TLSE. On the other
hand, a hypertensive state that is associated with oxidative stress in
RVLM will prevail because of the significantly less NOS II
expression and activity in RVLM of spontaneously hypertensive
rats [53]. It should be noted that the occurrence of oxidative stress
during experimental TLSE is not restricted to RVLM. Employing
the same experimental model, we showed previously [32] that
prolonged seizure prompted an increase in superoxide anion in the
hippocampal CA3 subfield. Interestingly, on reacting with the
simultaneously elevated NOS II-generated NO, the resultant
formation of peroxynitrite elicits apoptotic cell death in hippo-
campal CA3 neurons by reducing the activity of mitochondrial
respiratory enzyme Complex I.
Our observed transcriptional upregulation of bdnf and trkB genes
suggests that de novo synthesis of BDNF and TrkB in RVLM may
account for their augmented protein levels in RVLM during
experimental TLSE. BDNF can enter the central nervous system
by a rapid, saturable transport system of the blood-brain-barrier
[54]. Thus, the elevated serum BDNF concentration may further
contribute to its augmented level in RVLM. The present study
also revealed that the upregulated BDNF and TrkB exert an
antioxidant action in RVLM that leads to amelioration of brain
Figure 5. Activation of angiotensin AT1 receptor subtype in RVLM underlies the reduced baroreflex-mediated sympathetic
vasomotor tone during experimental TLSE. Temporal changes in MAP (A), power density of the BLF component (B), HR (C) or BRS (D) after
microinjection of KA (0.5 nmol) or PBS into the left hippocampal CA3 subfield (at arrow) of animals that received pretreatment by application into the
bilateral RVLM of distilled water (Veh), losartan (2 nmol) or PD123319 (2 nmol). Values are mean 6 SEM from 5–7 animals per experimental
group.*P,0.05 versus Veh+PBS group, and
+P,0.05 versus Veh+KA group at corresponding time-points in the post hoc Scheffe ´ multiple-range test.
B=preinjection baseline.
doi:10.1371/journal.pone.0033527.g005
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The differential results from treatments with TrkB-Fc and TrkA-
Fc further suggest that the antioxidant effect of BDNF against
oxidative stress in RVLM is mediated via TrkB. Our laboratory
demonstrated recently [29] that under chronic conditions, Ang II
induces superoxide-dependent upregulation of BDNF in RVLM
via phosphorylation of cAMP response element binding protein.
The Ang II-activated BDNF/TrkB signaling, in turn, suppresses
tissue superoxide level in RVLM through inhibition of p47
phox
phosphorylation. The present study revealed that it is unlikely that
this negative-feedback mechanism takes place in RVLM during
acute seizure. Pretreatment with losartan, tempol or apocynin did
not affect significantly the augmentation of BDNF/TrkB signaling
in RVLM during the first 3 h after the induction of experimental
TLSE.
Our results did support the notion that the upregulated BDNF/
TrkB signaling exerts its antioxidant action via inhibition of
p47
phox phosphorylation. We further demonstrated that by
decreasing the production of superoxide anion, BDNF and TrkB
in effect reduce the formation of peroxynitrite in RVLM without
affecting NOS II expression. Our laboratory reported recently that
activation of extracellular signal-regulated kinase (ERK) by
BDNF/TrkB signaling [55], followed by mitogen-activated
protein kinase signaling-interacting kinase [56] pathway in RVLM
is responsible for ameliorating brain stem cardiovascular regula-
tory dysfunction during experimental brain death. More impor-
tantly and relevant to the present study, ERK is able to desensitize
NADPH oxidase 1 (NOX 1) activity by phosphorylating NOX
activator 1 at its serine 282 residue, resulting in the suppression of
superoxide anion production [57]. It follow that ERK in the
RVLM may also play a role in the antioxidant actions of BDNF/
TrkB signaling during experiment TLSE by desensitizing the
NADPH oxidase/superoxide cascade.
At the NTS, BDNF signaling exerts a tonic inhibitory
modulation on primary afferent glutamatergic excitatory trans-
mission and neural activity [28]. Of note is that acute activation of
AT1R in RVLM potentiates glutamatergic neurotransmission
[40]. Since our results indicated that the augmented BDNF/TrkB
Figure 6. Upregulation of BDNF and TrkB in RVLM during experimental TLSE. Fold-changes in BDNF or TrkB mRNA against sham-control
detected by real-time PCR (A,C), temporal changes in tissue levels of BDNF detected by ELISA (B) or TrkB detected by Western blot analysis (D) in
tissues collected from bilateral RVLM 180 min (A,C,D) or 1, 2 or 3 h (B) after microinjection of KA (0.5 nmol) or PBS into the left hippocampal CA3
subfield. Values are mean 6 SEM of triplicate analyses from 5–6 animals per experimental group. *P,0.05 versus sham-control or PBS group in the
post hoc Scheffe ´ multiple-range test.
doi:10.1371/journal.pone.0033527.g006
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the level of transcription, it is possible that BDNF/TrkB signaling
may also exert an inhibitory modulation on glutamatergic
neurotransmission in RVLM during experimental TLSE. This
possibility is deemed unlikely because we observed that glutama-
tergic neurotransmission in RVLM is not involved in the reduced
MAP and baroreflex-mediated sympathetic vasomotor tone during
experimental TLSE.
In conclusion, the present study presented a novel mechanistic
view on the modus operandi whereby brain stem cardiovascular
dysregulation predisposes mortality following SE. We showed that
a reduction in baroreflex-mediated sympathetic vasomotor tone
already occurs during the seizure episodes. Whether deterioration
of the maintained baroreflex-mediated modulation of the heart
ensues over time therefore becomes a crucial determinant for post-
SE mortality to take place. We further showed that the repertoire
of cellular events in RVLM that leads to reduction in baroreflex-
mediated sympathetic vasomotor tone during experimental TLSE
includes activation of AT1R, followed by augmented level of
superoxide anion generated by the triggered p47
phox subunit of
NADPH oxidase and NOS II, leading to the formation of
peroxynitrite. Finally, the upregulated BDNF/TrkB signaling in
RVLM ameliorates brain stem cardiovascular dysregulation by
exerting an antioxidant action via inhibition of p47
phox phosphor-
ylation. This information offers a new vista in devising therapeutic
strategy or clinical management towards minimizing mortality
associated with TLSE.
Materials and Methods
Ethics statement
All experimental procedures carried out in this study were
approved by the Institutional Animal Care and Use Committee of
the Kaohsiung Chang Gung Memorial Hospital (97005), and were
in compliance with the guidelines for animal care and use set forth
by that committee. All efforts were made to reduce the number of
animals used and to minimize animal suffering during the
experiment.
Animals
Specific pathogen-free adult, male Sprague-Dawley rats (260 to
325 g, n=253) purchased from the Experimental Animal Center
of the National Science Council and BioLASCO, Taiwan,
Republic of China were used. They were housed in an Association
for Assessment and Accreditation of Laboratory Animal Care
(AAALAC) International-accredited animal facility under temper-
ature control (24–25uC) and 12-h light-dark cycle. Standard
laboratory rat chow and tap water were available ad libitum.
General preparation
Preparatory surgery, including tracheal intubation and cannu-
lation of the femoral artery and vein was performed under an
induction dose of pentobarbital sodium (50 mg/kg, i.p.). Rats
received thereafter intravenous infusion of propofol (20–25 mg/
kg/h; Zeneca, Macclesfield, England), which provided satisfactory
Figure 7. Upregulation of TrkB in RVLM ameliorates the reduced baroreflex-mediated sympathetic vasomotor tone during
experimental TLSE. Temporal changes in MAP (A), power density of the BLF component (B), HR (C) or BRS (D) after microinjection of KA (0.5 nmol)
or PBS into the left hippocampal CA3 subfield (at arrow) of animals that received pretreatment by application into the bilateral RVLM of 0.1 M PBS
(Veh), TrkB-Fc (0.75 or 1.5 pmol) or TrkA-Fc (1.5 pmol). Values are mean 6 SEM from 5–7 animals per experimental group.*P,0.05 versus Veh+PBS
group, and
+P,0.05 versus Veh+KA group at corresponding time-points in the post hoc Scheffe ´ multiple-range test. B=preinjection baseline.
doi:10.1371/journal.pone.0033527.g007
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stem cardiovascular regulation [58]. During the recording sessions,
animals were allowed to breathe spontaneously with room air, and
body temperature was maintained at 37uC by a heating pad.
Experimental temporal lobe status epilepticus
An experimental model [30–32] that mimics TLSE clinically
was used. As in our previous study, KA (Tocris, Ellisville, MO,
USA) dissolved in 0.1 M phosphate buffered saline (PBS, pH 7.4),
at a concentration of 0.5 nmol, was microinjected stereotaxically
(3.0–3.5 mm posterior to bregma, 1.4–2.2 mm from the midline,
and 3.5–4.0 mm below the cortical surface) into the CA3 subfield
of hippocampus on the left side. A small range of coordinates was
adopted to adjust for the slight difference in brain size because of
body weight of the animals. The volume of microinjection was
restricted to 50 nl, and was delivered via a glass micropipette
connected to a 0.5-ml microsyringe (Hamilton, Reno, NV, USA).
Possible volume effect of microinjection was controlled by injecting
the same amount of PBS in a separate group of animals. The
hEEG signals were recorded from the right CA3 subfield by a
stainless-steel bipolar concentric electrode (Rhodes Medical
Instruments, Woodland Hills, CA; tip diameter: 100 mm), using
the same stereotaxic coordinates as for microinjection. Bioelectri-
cal signals were amplified and filtered (0.1 to 300 Hz) by a
differential amplifier (A-M System, Sequim, WA, USA). The
hEEG signals were simultaneously subject to continuous on-line
and real-time spectral analysis (EEG10a, Notocord, Croissy-Sur-
Seine, France). We quantified the magnitude of hEEG activity by
calculating the RMS value. The frequency domain of hEEG
signals was evaluated by calculating the MPF values. As a routine,
hEEG signals and their RMS or MPF values were followed for
180 min after the induction of experimental TLSE.
Recording of cardiovascular parameters and evaluation
of baroreflex responses
AP recorded from the femoral artery was analyzed by an
arterial blood pressure analyzer (APR31a, Notocord) to obtain
SBP and PI. Continuous, on-line and real-time auto-spectral
analysis (SPA10a, Notocord) of SBP signals was used to detect
temporal fluctuations in the BLF (0.25–0.8 Hz) bands, the power
density of which was used as the index for baroreflex-mediated
sympathetic vasomotor tone [34]. To evaluate baroreflex-mediat-
ed cardiac responses, we employed a baroreflex sequence analyzer
(BRS10a,) to determine the BRS based on on-line detection of
spontaneous baroreflex sequences that were detected when SBP
and PI increased or decreased simultaneously [35]. In addition,
cross-spectral analysis of SBP and PI spectrum (CSA10a,
Notocord) was used to reveal the gain of transfer function at the
LF (0.25–0.8 Hz) and high-frequency (HF; 0.8–2.4 Hz) bands,
which denotes respectively the efficacy of baroreflex-mediated
Figure 8. Upregulation of BDNF in RVLM ameliorates the reduced baroreflex-mediated sympathetic vasomotor tone during
experimental TLSE. Temporal changes in MAP (A), power density of the BLF component (B), HR (C) or BRS (D) after microinjection of KA (0.5 nmol)
or PBS into the left hippocampal CA3 subfield (at arrow) of animals that received pretreatment by application into the bilateral RVLM of distilled
water (Veh), an antisense (ASON; 50 or 100 pmol) or sense oligonucleotide (SON) against bdnf gene (100 pmol). Values are mean 6 SEM from 5–7
animals per experimental group.*P,0.05 versus Veh+PBS group, and
+P,0.05 versus Veh+KA group at corresponding time-points in the post hoc
Scheffe ´ multiple-range test. B=preinjection baseline.
doi:10.1371/journal.pone.0033527.g008
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[35]. Concurrent changes in the cardiovascular parameters and
the four indices for baroreflex responses were followed for 180 min
after the induction of experimental TLSE.
Microinjection of test agents into RVLM
To produce site-specific pretreatments, test agents were
microinjected bilaterally and sequentially into RVLM via a glass
micropipette connected to a 0.5-ml Hamilton microsyringe
[29,37,40,48]. The coordinates used were: 4.5 to 5 mm posterior
to the lambda, 1.8 to 2.1 mm lateral to the midline and 8.1 to
8.4 mm below the dorsal surface of the cerebellum. Again, a small
range of coordinates was used to adjust for the slight difference in
brain size because of body weight of the animals. As a routine, a
total volume of 50 nl was delivered to each side of RVLM over 2–
3 min to allow for complete diffusion of the test agents. Test agents
used included a fluorescence indicator for superoxide anion [37],
hydroethidine (Molecular Probes, Eugene, OR, USA); a superox-
ide dismutase mimetic [38], tempol (Calbiochem, San Diego, CA,
USA); a specific antagonist of NADPH oxidase [39], apocynin
(Calbiochem); an AT1R antagonist [41], losartan (Tocris); an
AT2R antagonist [42], PD123319 (Tocris); a recombinant
human TrkB-Fc fusion protein (R&D Systems, Minneapolis,
MN, USA); a recombinant human TrkA-Fc fusion protein (R&D
Systems); an antisense oligonucleotide against bdnf gene (59-
TCTTCCCCTTTTGGT-39) and its sense control (59-AC-
CAAAAGGGGAAGA-39) (Quality Systems, Taipei, Taiwan); or
a NMDA antagonist, MK-801 [44] (Sigma-Aldrich, St. Louis,
MO, USA). The doses were adopted from our previous reports
[29,31,32,36,40,59] that used those test agents for the same
Figure 9. BDNF and TrkB reduce the upregulated peroxynitrite
levels in RVLM during experimental TLSE. Illustrative gels or
summary of changes in NOS II detected by Western blot analysis (A) or
nitrotyrosine (experimental index for peroxynitrite) detected by ELISA
(B) in samples collected from bilateral RVLM of sham-control or 180 min
after microinjection of KA (0.5 nmol) or PBS into the left hippocampal
CA3 subfield of animals that received pretreatment by application into
the bilateral RVLM of distilled water or 0.1 M PBS (Veh), BDNF ASON
(100 pmol) or TrkB-Fc (1.5 pmol). Values are mean 6 SEM of triplicate
analyses on individual samples obtained from 5–6 animals per
experimental group. *P,0.05 versus sham-control or Veh+PBS group,
and
+P,0.05 versus Veh+KA group in the post hoc Scheffe ´ multiple-
range test.
doi:10.1371/journal.pone.0033527.g009
Figure 10. Upregulation of BDNF and TrkB is not a conse-
quence of oxidative stress in RVLM. Fold-changes in BDNF (A) or
TrkB (B) mRNA against sham-control detected by real-time PCR in
tissues collected from bilateral RVLM 180 min after microinjection of KA
(0.5 nmol) or PBS into the left hippocampal CA3 subfield of animals that
received pretreatment by application into the bilateral RVLM of distilled
water or 1% DMSO (Veh), losartan (2 nmol), PD123319 (2 nmol), tempol
(200 pmol) or apocynin (2 nmol). Values are mean 6 SEM of triplicate
analyses from 5–6 animals per experimental group. *P,0.05 versus
sham-control or PBS group in the post hoc Scheffe ´ multiple-range test.
doi:10.1371/journal.pone.0033527.g010
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sulfoxide (DMSO; Sigma-Aldrich) (hydroethidine, apocynin);
distilled water (losartan, PD123319, tempol, antisense or sense
oligonucleotide against bdnf gene, MK-801); or 0.1 M PBS (TrkB-
Fc or TrkA-Fc fusion protein). Possible volume effect of
microinjection was controlled by injecting the same amount of
solvent. It should be mentioned that none of these solvents
exhibited significant influence on MAP, HR, power density of BLF
component of SBP spectrum and BRS (Table 1). All test agents or
their vehicles were given 30 min before KA administration, with
the exception that antisense or sense oligonucleotide was given
24 h prior to the induction of experimental TLSE. To avoid the
confounding effects of drug interactions, each animal received only
one test agent.
Figure 11. BDNF and TrkB do not interact with AT1R in RVLM. Illustrative gels or summary of fold changes in angiotensin receptor subtype 1
(AT1R) or subtype 2 (AT2R) mRNA (A,C) against sham-control detected by real-time PCR (A,C) or AT1R or AT2R protein detected by Western blot
analysis (B,D) in samples collected from bilateral RVLM 180 min after microinjection of KA (0.5 nmol) or PBS into the left hippocampal CA3 subfield of
animals that received pretreatment by application into the bilateral RVLM of distilled water or 0.1 M PBS (Veh), BDNF ASON or SON (100 pmol), TrkB-
Fc (1.5 pmol) or TrkA-Fc (1.5 pmol). Values are mean 6 SEM of triplicate analyses on individual samples obtained from 5–6 animals per experimental
group. *P,0.05 versus sham-control or PBS group in the post hoc Scheffe ´ multiple-range test. Note that in (B,D), dividing lines are placed on the gel
images to denote groupings of images from different parts of the same gel or from different gels.
doi:10.1371/journal.pone.0033527.g011
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Superoxide anion in RVLM was determined semi-quantitative-
ly by the intensity of fluorescence emitted by 2-hydroxyethidium,
the specific reaction product between hydroethidine and superox-
ide. In brief, hydroethidine (1 mg/ml) was microinjected into the
bilateral RVLM, 30 min before the commencement of experimental
manipulations. At the conclusion of the experiment, animals were
perfused transcardially with warm isotonic saline solution, followed
by ice-cold4% paraformaldehyde in 0.1 M PBS.The brain stem was
removed, postfixed by submersion in the latter solution and
cryoprotected by 30% sucrose in 0.1 M PBS. Frozen transverse
sections of the medulla oblongata were cut on a cryostat (Leitz,
Welzlar, Germany) and mounted on glass slides with K-Y jelly
(Johnson & Johnson, New Brunswick, NJ, USA). Viewed under a
laser scanning confocal microscope (FV10i, Olympus, Tokyo, Japan),
the intensity of fluorescence relative to background in RVLM, which
was designated the area of interest, was determined by an analysis
program (Fluoview FV10-ASW Version.02.01; Olympus).
Figure 12. Glutamatergic neurotransmission in RVLM is not involved in the reduced baroreflex-mediated sympathetic vasomotor
tone during experimental TLSE. Temporal changes in MAP (A), power density of the BLF component (B), HR (C) or BRS (D) after microinjection of
KA (0.5 nmol) or PBS into the left hippocampal CA3 subfield (at arrow) of animals that received pretreatment by application into the bilateral RVLM of
distilled water (Veh) or MK-801 (500 pmol). Values are mean 6 SEM from 5–7 animals per experimental group. No significant difference exists
(P.0.05) between treatment groups in two-way ANOVA with repeated measures.
doi:10.1371/journal.pone.0033527.g012
Table 1. Lack of effects of the solvents on baseline cardiovascular parameters and baroreflex responses.
Treatment MAP (mmHg) HR (bpm) BLF (mmHg
2) BRS (ms/mmHg)
0.1 M PBS Before 118.9567.62 381.4467.62 12.8761.49 0.9860.07
After 117.7561.91 376.47613.8 11.6361.36 1.0160.08
Distilled water Before 117.9461.43 381.42614.77 11.7261.44 0.9760.04
After 118.1262.00 385.85615.95 12.3761.99 1.0460.07
1% DMSO Before 118.7562.01 383.9613.68 11.8161.37 0.9960.05
After 116.0762.11 370.05610.36 12.5361.84 1.0360.05
Values are mean 6 SEM from 5–7 animals per experimental group, and were determined 30 min before and 30 min after experimental manipulations. No significant
difference exists (P.0.05) between treatment groups in ANOVA.
doi:10.1371/journal.pone.0033527.t001
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With minor exceptions, we routinely collected tissue samples
from RVLM [29,37,40,48] at 3 h after the induction of
experimental TLSE. Medullary tissues collected from anesthetized
animals but without treatment served as sham-controls. As a
routine, microinjection sites were visually verified and recorded
after the slice of medulla oblongata that contains RVLM (0.5 to
1.5 mm rostral to the obex) was obtained. Tissues from both sides
of the ventrolateral medulla, at the level of RVLM were collected
by micropunches made with a 1 mm (id) stainless steel bore to
cover the anatomical boundaries of RVLM. The concentration of
proteins extracted was determined by the BCA Protein Assay
(Pierce, Rockford, IL, USA).
Western blot analysis
Western blot analysis [29,40,48] was carried out using a rabbit
polyclonal antiserum against TrkB (Novus Biologicals, Littleton,
CO, USA), AT1R or AT2R (Chemicon, Temecula, CA, USA) or
NOS II (Santa Cruz Biotechnology, Santa Cruz, CA, USA); or a
mouse monoclonal antiserum against b-actin (Chemicon). This
was followed by incubation with horseradish peroxidase-conju-
gated donkey anti-rabbit IgG (GE Healthcare, Little Chalfont,
Buckinghamshire, UK) for TrkB, AT1R or AT2R; or sheep anti-
mouse IgG (GE Healthcare) for b-actin. Specific antibody-antigen
complex was detected by an enhanced chemiluminescence
Western blot detection system (Santa Cruz Biotechnology). The
amount of protein was quantified by the ImageMaster software
(Amersham Pharmacia Biotech, Buckinghamshire, UK), and was
expressed as the ratio relative to b-actin protein.
Immunoprecipitation and immunoblot analysis
Protein extracts from the cytosolic fraction of samples from
RVLM were immunoprecipitated with affinity-purified goat
polyclonal anti-p47
phox antiserum conjugated with protein G-
agarose beads. Immunoprecipitation was performed [29,48] at
4uC overnight and the precipitated beads were washed three times
with ice-cold lysis buffer. The agarose beads resuspended in the
loading buffer were boiled for 10 min to dissociate the immuno-
complexes from the beads. Western blot analysis of phosphoserine
or p47
phox from proteins immunoprecipitated by anti-p47
phox
antiserum was carried out as described above.
Isolation of RNA and real-time PCR
Total RNA from RVLM was isolated with a Total RNA Mini
kit (Geneaid, Taipei, Taiwan) according to the manufacturer’s
instructions. All RNA isolated was quantified by spectrophotom-
etry and the optical density (OD) 260/280 nm ratio was
determined. Reverse transcriptase reaction was performed using
a Transcriptor First strand cDNA Synthesis kit (Roche, Mann-
heim, Germany). Real-time PCR analysis [29,48] was performed
by amplification of cDNA using a LightCycler (Roche). PCR
reaction for each sample was carried out in triplicate for all the
cDNA and for the GAPDH control. Primers were designed using
the sequence information of the NCBI database by Roche
LightCycler probe design software 2.0, and oligonucleotides were
synthesized by Quality Systems (Taipei, Taiwan).
The primer pairs used for amplification of target genes were:
BDNF (Genbank Accession: NM_012513 ):
Forward primer: 59-GTTAGGAGAAGTCAAGCTGGA-39
Reverse primer: 59-AAGCAATTGTTTGCCTCTTT-39
TrkB (Genbank Accession: NM_001163168):
Forward primer: 59-CATCTATCTACCTATCATGTCTGG-39
Reverse primer: 59-AATGTTGCTGAAATGGTTGTTAT-39
AT1R (Genbank Accession: NM_030985):
Forward primer: 59-CCTCTGACTAAATGGCTTACG-39
Reverse primer: 59-CATCTATTAATGCAAGACGGC-39
AT2R (Genbank Accession: NM_012494):
Forward primer: 59-TGGGAGTCTCTGACAGTTC-39
Reverse primer: 59-AAATGCTTATCTGCCGGT-39
GAPDH (Genbank Accession: NM_017008):
Forward primer: 59-CTTCTCTTGTGACAAAGTGGA-39
Reverse primer: 59-TTAGCGGGATCTCGCTC-39
Fluorescence signals from the amplified products were quanti-
tatively assessed using the LightCycler software program (version
3.5). The second derivative maximum mode was chosen with
baseline adjustment set in the arithmetic mode. The relative
changes in mRNA expression were determined by the fold-change
analysis, in which Fold change=2
2[DDCt], where DDCt=(Ctgene
2CtGAPDH)KA treatment2(Ctgene2CtGAPDH)sham control). Note that
Ct value is the cycle number at which fluorescence signal crosses
the threshold.
Determination of BDNF or nitrotyrosine in serum or
RVLM
The level of BDNF in serum or tissues collected from RVLM
was determined by a commercial ELISA kit (Millipore, Billerica,
MA, USA). Nitrotyrosine in RVLM was similarly determined by a
commercial ELISA kit (Cell Biolabs, San Diego, CA, USA).
Quantified of BDNF or nitrotyrosine was carried out by measuring
the absorbance at 450 nm in conjunction with spectrophotometry
(Thermo Scientific, Waltham, MA, USA). Blood (200 ml) drawn
from the femoral artery was centrifuged to obtain serum samples,
which were frozen at 280uC until analysis.
Statistical analysis
All values are expressed as mean 6 SEM. The averaged value
of MAP, HR, BRS, LF gain or HF gain calculated every 20 min
after administration of test agents or vehicle, the sum total of
power density for the BLF component in the SBP spectrum over
20 min, and changes in fluorescence intensity of 2-hydroxyethi-
dium, real-time PCR products or protein expression in RVLM
during experimental TLSE, was used for statistical analysis. One-
way or two-way ANOVA with repeated measures was used, as
appropriate, to assess group means. This was followed by the
Scheffe ´ multiple-range test for post hoc assessment of individual
means. P,0.05 was considered to be statistically significant.
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